Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00.</li><li>Atossa is a clinical-stage biopharmaceutical company focused on rare diseases and oncology with a significant unmet need.</li><li>The lead development compound is (Z)-endoxifen, which is being advanced across multiple indications, including McCune-Albright Syndrome (MAS), breast cancer, and other endocrine-driven conditions.</li></ul>

We are initiating coverage of Atossa Therapeutics, Inc. (ATOS) with a valuation of $22.00.Atossa is a clinical-stage biopharmaceutical company focused on rare diseases and oncology with a significant unmet need.The lead development compound is (Z)-endoxifen, which is being advanced across multiple indications, including McCune-Albright Syndrome (MAS), breast cancer, and other endocrine-driven conditions.

Atossa Therapeutics

Atossa Therapeutics Inc - May 13, 2026